Fmr LLC increased its stake in Centessa Pharmaceuticals plc (NASDAQ: CNTA) by 4.6% in Q3, owning 2,916,494 shares valued at $46.6 million. Other institutional investors also raised their holdings, bringing institutional ownership to 82.01%. Analysts have upgraded CNTA, with Jefferies setting a target price of $19, while BMO’s target rose to $35. Centessa’s stock opened at $18.67, with a market cap of $2.46 billion. The company reported quarterly earnings of -$0.37 per share, surpassing estimates. CEO Saurabh Saha sold 175,000 shares recently, reducing his stake by 18.38%. Centessa focuses on developing treatments for various conditions.